GSK PLC (GSK)
40.86
-0.38
(-0.92%)
USD |
NYSE |
Apr 24, 16:00
40.76
-0.10
(-0.24%)
After-Hours: 20:00
GSK Cash from Financing (Quarterly): -4.425B for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -4.425B |
September 30, 2023 | -2.235B |
June 30, 2023 | 27.30M |
March 31, 2023 | -386.53M |
December 31, 2022 | -1.524B |
September 30, 2022 | -1.840B |
June 30, 2022 | -6.313B |
March 31, 2022 | 10.70B |
December 31, 2021 | -3.802B |
September 30, 2021 | -1.857B |
June 30, 2021 | -2.885B |
March 31, 2021 | -1.897B |
December 31, 2020 | -2.722B |
September 30, 2020 | -5.718B |
June 30, 2020 | -3.216B |
March 31, 2020 | -1.348B |
December 31, 2019 | -3.482B |
September 30, 2019 | -2.426B |
June 30, 2019 | -1.211B |
March 31, 2019 | 4.769B |
December 31, 2018 | -4.430B |
September 30, 2018 | -2.087B |
June 30, 2018 | -1.614B |
March 31, 2018 | -393.51M |
December 31, 2017 | -4.150B |
Date | Value |
---|---|
September 30, 2017 | -925.52M |
June 30, 2017 | -1.294B |
March 31, 2017 | -1.869B |
December 31, 2016 | -2.817B |
September 30, 2016 | -2.276B |
June 30, 2016 | -1.689B |
March 31, 2016 | -1.880B |
December 31, 2015 | -1.345B |
September 30, 2015 | -3.196B |
June 30, 2015 | -3.613B |
March 31, 2015 | -2.701B |
December 31, 2014 | -2.662B |
September 30, 2014 | -253.37M |
June 30, 2014 | -1.677B |
March 31, 2014 | -4.284B |
December 31, 2013 | -2.595B |
September 30, 2013 | -1.762B |
June 30, 2013 | -3.197B |
March 31, 2013 | -2.260B |
December 31, 2012 | -1.603B |
September 30, 2012 | -1.909B |
June 30, 2012 | 158.84M |
March 31, 2012 | -1.957B |
December 31, 2011 | -2.039B |
September 30, 2011 | -2.921B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.313B
Minimum
Jun 2022
10.70B
Maximum
Mar 2022
-1.924B
Average
-2.235B
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
AstraZeneca PLC | -291.00M |
Haleon PLC | -- |
Novo Nordisk A/S | -1.424B |
Pfizer Inc | 5.442B |
Sanofi SA | -- |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 3.899B |
Cash from Investing (Quarterly) | 374.35M |
Free Cash Flow | 5.505B |
Free Cash Flow Per Share (Quarterly) | 1.436 |
Free Cash Flow to Equity (Quarterly) | 6.965B |
Free Cash Flow to Firm (Quarterly) | 3.286B |
Free Cash Flow Yield | 6.18% |